Activity Provided By:

ACHL

Revolutionizing T2T in RA: Future Paradigms with JAK Inhibitors

Overview / Abstract:	How can clinicians be assured they have the most up-to-date information for improving their patients’ outcomes in RA care? In this clinical commentary, leading infectious disease expert Kevin Winthrop, MD, MPH, and Rheumatology experts Philip Mease, MD, MACR, and William F.C. Rigby, MD, discuss the latest evidence, safety data, and potential roles with the available and emerging JAK inhibitors, as well as current treat-to-target RA paradigms. Because the patient plays such a critical role in shared decision-making, this activity will also include patient ambassadors sharing their perspectives, experiences, and treatment goals. Bonus supplemental material includes: • Understanding Discordance in RA Care • Patient Perspectives on Shared Decision-Making • What Patients with RA Want Their Rheumatologists to Know • EULAR 2020 RA Updates
Expiration	Jul 24, 2021
Discipline(s)	Nurse Practitioner , Nursing CNE, Pharmacy CPE, Physician CME, Physician Assistant CME
Format	Webinar / Webcast / Video
Credits / Hours	1.0
Accreditation	ACCME
Presenters / Authors / Faculty	Kevin Winthrop, MD, MPH (Chair) Professor, Division of Infectious Diseases Schools of Medicine and Public Health Oregon Health and Sciences University Portland, OR Philip Mease, MD, MACR (Faculty) Director, Rheumatology Research Division Swedish Medical Center/Providence-St. Joseph Health Clinical Professor, University of Washington School of Medicine Seattle, WA William F.C. Rigby, MD (Faculty) Professor of Medicine, Microbiology and Immunology Division of Rheumatology Vice Chairman, Academic Affairs Department of Medicine Dartmouth Medical School Dartmouth-Hitchcock Medical Center Lebanon, NH
Activity Specialities / Related Topics	Allergies / Allergic Reactions, Family Medicine, Immunology / Immunosuppression, Internal Medicine, OB/GYN / Women's Health, Primary Care, Rheumatology / Arthritis
Sponsors / Supporters / Grant Providers	Supported by an educational grant from Gilead Sciences, Inc.
Keywords / Search Terms	ACHL winthrop, MD, rigby, MD, mease, MD, inflammatory disease, rheumatoid arthritis, RA, signaling pathway, JAK inhibitor, inflammatory diseases, autoimmune disorders, janus kinase, therapies, immune-mediated inflammatory diseases, JAK1, JAK2, JAK3, TYK2, JAK/STAT signaling, cytokine-mediated inflammatory diseases, DMARDs, chronic inflammation, emerging therapies, novel rheumatology drugs, rheumatology, JAKi, JAKis Free CE CME

Access Activity

CORE Higher Education Group, CESearchEngine.com, and our advertising partners do not endorse and do not verify the accuracy of the content in the activities presented on the CESearchEngine.com website or within our mobile apps.CORE Higher Education Group, CESearchEngine.com, and our advertising partners are not responsible for errors, omissions, or misrepresentations contained within activities presented on the CESearchEngine website or within our mobile apps. For complete details, please read the CESearchEngine.com Terms of Service. Site Map